Literature DB >> 18971180

[Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR].

Xiu-ying Cui1, Yun-jie Guo, He-rui Yao.   

Abstract

OBJECTIVE: To analyze the difference in microRNAs expression between MCF-7 and MCF-7/ADR cells and explore the association between microRNA and drug resistance of breast cancer.
METHODS: The drug resistance of MCF-7/ADR cells was evaluated using MTT assay and flow cytometry. Microarray technique and RT-PCR were used to analyze the differential expressions of the microRNA between MCF-7 and MCF-7/ADR cells.
RESULTS: The drug resistance index of MCF-7/ADR cells relative to the parental MCF-7 cells was 33.2. The percentages of the side population in MCF-7/ADR and MCF-7 cells were (9.50-/+0.9)% and (0.85-/+0.2)%, respectively. Microarray analysis of MCF-7 to MCF-7/ADR cells identified 36 differentially expressed genes, including 16 up-regulated and 20 down-regulated genes in MCF-7/ADR cells. RT-PCR identified 14 microRNAs that were differentially expressed between MCF-7 and MCF-7/ADR cells, including 7 up-regulated and 7 down-regulated ones in MCF-7/ADR cells. Of these differentially expressed microRNAs, mir-221, mir222, mir-130a, and mir-155 showed significantly increased expression, and mir200a, mir-200b, mir-200c, and mir-421 showed significantly lowered expression in MCF-7/ADR cells as indicated by the results of microarray analysis and RT-PCR.
CONCLUSION: MCF-7/ADR cells show a different microRNA expression profile from its parental MCF-7 cells, suggesting the involvement of microRNAs in tumor cell drug resistance. This finding provides a experimental basis for further study of mechanism underlying the drug resistance of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971180

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  9 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

Review 2.  Role of miR-155 in drug resistance of breast cancer.

Authors:  Dan-dan Yu; Meng-meng Lv; Wei-xian Chen; Shan-liang Zhong; Xiao-hui Zhang; Lin Chen; Teng-fei Ma; Jin-hai Tang; Jian-hua Zhao
Journal:  Tumour Biol       Date:  2015-03-06

Review 3.  MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications.

Authors:  Wei Tian; Junqing Chen; Haifei He; Yongchuan Deng
Journal:  Clin Transl Oncol       Date:  2012-08-23       Impact factor: 3.405

4.  Increased expression of miR-421 in human gastric carcinoma and its clinical association.

Authors:  Zhen Jiang; Junming Guo; Bingxiu Xiao; Ying Miao; Rong Huang; Dong Li; Yuanyuan Zhang
Journal:  J Gastroenterol       Date:  2009-10-03       Impact factor: 7.527

5.  Effect of miRNA-19a antisense oligonucleotide and Ara-C on the proliferation and apoptosis of HL60 cells.

Authors:  Shijie Bao; Dongmei He; Jinrong Zeng; Yanrong Zhang; Shengting Chen
Journal:  Ann Transl Med       Date:  2019-06

6.  MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.

Authors:  Ningwei Li; Lingyun Yang; Hongjing Wang; Tao Yi; Xibiao Jia; Cen Chen; Pan Xu
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

7.  miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.

Authors:  Man Gao; Lingling Miao; Mingxia Liu; Chenggang Li; Cunzhi Yu; Hong Yan; Yongxiang Yin; Yizheng Wang; Xinming Qi; Jin Ren
Journal:  Oncotarget       Date:  2016-09-13

8.  Dissecting the dynamics of dysregulation of cellular processes in mouse mammary gland tumor.

Authors:  Wieslawa I Mentzen; Matteo Floris; Alberto de la Fuente
Journal:  BMC Genomics       Date:  2009-12-13       Impact factor: 3.969

9.  Identification of microRNAs and mRNAs associated with multidrug resistance of human laryngeal cancer Hep-2 cells.

Authors:  Wanzhong Yin; Ping Wang; Xin Wang; Wenzhi Song; Xiangyan Cui; Hong Yu; Wei Zhu
Journal:  Braz J Med Biol Res       Date:  2013-06-12       Impact factor: 2.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.